Novo Nordisk A/S
NYSE: NVO
Stock price
37.52 USD
(+7.02%) 5 years
Financial Performance
5Y price score: 10
against the S&P 500 Index over a five-year period.
A score of 100 indicates that the stock did as well as the S&P 500 Index.
A score below 100 means the stock underperformed the index,
while a score above 100 means it outperformed the S&P 500.
10Y return: 62.4%
US$ Per
Share
Earnings per share
Free cash flow per share
Stock price
By default your notes are visible only to you.
35.1
52-week range
81.4
Your model inputs
| Required return / cost of capital |
| FCFF terminal growth rate |
Valuation
Free Cash Flow Yield
17.4 %
Dividend Yield TTM
5 %
Market cap $
$ 166,740.4
Price / Earnings TTM
1.6
Price / Book TTM
5.4
PEG TTM
0.9
Earnings growth and return
LTM
5YR
10YR
Total return (price & dividends)
(36.7) %
20.8 %
62.4 %
Free cash flow per share growth
(58.2) %
2.1 %
5.4 %
Earnings per share growth
1.8 %
155.6 %
240.7 %
Founded: 1,923
Employees: 69,260
Business Summary:
all figures in DKK Millions except per share data
Periods:
View:
Forecast:
Averages
based on historical growth rates (CAGR) and average margins for last 10 or max, available and up to 10 years.
Analysts
Average Revenue and Net Income forecast estimates from analysts who cover the stock.
Custom
you can edit default forecast based on averages or analysts consensus and use it to calculate fair value based on your assumptions.
ㅤ
Please log in / sign up view historical financials. It is free under TopFunds
Light plan.
Increase
Decrease
Total
| Required return / cost of capital |
| FCFF terminal growth rate |
| Free cash flow forecast |
| Terminal value |
| ㅤPV breakdown |
| Enterprise value / PV of FCF |
| ㅤPlus / (Less): Net Debt |
| ㅤLess: preferred stock |
| ㅤLess: minority interest |
| Market cap |
| ㅤNumber of shares |
| Price per share |
Please log in / sign up to calculate fair value based on selected inputs
Latest Earnings Call Takeaways
2025 Q4 (Feb 4, 2026)
1) Strategic Focus and Leadership Changes
- Novo Nordisk achieved 10% sales growth and 6% operating profit growth in 2025, emphasizing a strategic focus on obesity and diabetes care.
- The company has doubled its sales and operating profit since 2019, with obesity care sales soaring from DKK 6 billion to DKK 82 billion.
- Key leadership changes were announced, with Dave Moore and Ludovic Helfgott departing. Jamey Millar and Hong Chow will join the executive team, bringing extensive industry experience.
- The company aims to expand access to its therapies, having reached an additional 16 million patients in obesity and diabetes care.
2) Financial and Segment Results
- Total sales increased by 10%, with U.S. operations growing by 8% and International Operations by 14%.
- Obesity care sales surged 31%, driven by the success of Wegovy, which launched in 35 new countries and generated DKK 28 billion in sales, a 134% increase.
- Rare Disease sales rose by 9%, primarily from the uptake of Sogroya.
- Gross margin decreased to 81% from 84.7% in 2024, impacted by restructuring costs and amortization related to acquisitions.
3) Operational Plans and Product Pipeline
- The FDA approved the Wegovy pill, the first oral GLP-1 for obesity, which launched in January 2026 with promising early uptake.
- Upcoming trials include CagriSema and zenagamtide, with significant weight loss efficacy demonstrated in Phase III trials.
- The company plans to expand its obesity and diabetes markets through new online channels and partnerships, alongside the rollout of new products.
4) Guidance and Outlook
- For 2026, Novo Nordisk expects adjusted sales growth to decline by 5% to 13% at constant exchange rates, reflecting pricing headwinds and competitive pressures.
- The guidance incorporates anticipated challenges from the 340B Drug Pricing Program and increased competition, particularly in the U.S.
- Despite headwinds, the company remains optimistic about expanding patient reach and volume growth in obesity and diabetes care.
5) Missing Information and Final Remarks
- The transcript lacks specific figures on the expected impact of generic competition in International Operations, particularly in Canada.
- Bottom line: Novo Nordisk is positioned for continued growth in obesity and diabetes care despite anticipated pricing pressures in 2026, supported by a robust pipeline and strategic leadership changes. The focus remains on expanding patient access and maintaining market leadership in GLP-1 therapies.
Novo Nordisk A/S — Financial Overview, Stock Price, Market Cap
Novo Nordisk A/S is a company. Founded in 1923. As of April 13, 2026, the company's market capitalization is $166740437643 with a current stock price of $37.52.